Latest filings (excl ownership)
8-K
January 2025 Corporate Presentation
13 Jan 25
424B3
Prospectus supplement
18 Dec 24
EFFECT
Notice of effectiveness
17 Dec 24
S-1
IPO registration
2 Dec 24
8-K
Regulation FD Disclosure
21 Nov 24
10-Q
2024 Q3
Quarterly report
18 Nov 24
8-K
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
18 Nov 24
8-K
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
18 Nov 24
NT 10-Q
Notice of late quarterly filing
14 Nov 24
8-K
All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline
12 Nov 24
8-K
Neurogene Announces Oversubscribed $200 Million Private Placement
4 Nov 24
10-Q
2024 Q2
Quarterly report
9 Aug 24
8-K
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
9 Aug 24
8-K
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
7 Aug 24
8-K
June 2024 Corporate Presentation
21 Jun 24
8-K
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
18 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 24
8-K
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
3 Jun 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
10 May 24
8-K
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
7 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Departure of Directors or Certain Officers
24 Apr 24
8-K
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
22 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett
4 Mar 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
S-8
Registration of securities for employees
20 Feb 24
8-K
Neurogene Announces Business Update and 2024 Outlook
5 Jan 24
8-K
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
19 Dec 23
425
Business combination disclosure
6 Dec 23
8-K
Other Events
6 Dec 23
425
Business combination disclosure
4 Dec 23
8-K
Other Events
4 Dec 23
425
Business combination disclosure
30 Nov 23
EFFECT
Notice of effectiveness
14 Nov 23
Latest ownership filings
SC 13G/A
Redmile Group, LLC
14 Feb 25
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 25
SC 13G/A
Casdin Capital, LLC
14 Feb 25
SC 13G/A
JANUS HENDERSON GROUP PLC
14 Feb 25
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 25
SC 13G
COMMODORE CAPITAL LP
11 Dec 24
4
SRINIVAS AKKARAJU
27 Nov 24
3
SRINIVAS AKKARAJU
27 Nov 24
SC 13G/A
Samsara BioCapital, L.P.
27 Nov 24
4
Christine Mikail Cvijic
25 Nov 24
4
Rachel McMinn
25 Nov 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Nov 24
SC 13G/A
JANUS HENDERSON GROUP PLC
14 Nov 24
SC 13G/A
Cormorant Asset Management, LP
14 Nov 24
SC 13G
RTW INVESTMENTS, LP
14 Nov 24
SC 13G
FMR LLC
12 Nov 24
SC 13G
Casdin Capital, LLC
8 Nov 24
SC 13G
BlackRock Inc.
8 Jul 24
4
Robert Keith Woods
17 Jun 24
4
ROHAN PALEKAR
17 Jun 24
4
ROBERT BAFFI
17 Jun 24
4
Sarah B. Noonberg
17 Jun 24
4
Cory S. Freedland
17 Jun 24
4
Rachel McMinn
14 Mar 24
4
Christine Mikail Cvijic
14 Mar 24
4
Stuart Cobb
14 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G
Samsara BioCapital, L.P.
14 Feb 24
SC 13G
Cormorant Asset Management, LP
14 Feb 24
SC 13G
JANUS HENDERSON GROUP PLC
14 Feb 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
144
Notice of proposed sale of securities
6 Feb 24
4
Robert Keith Woods
18 Jan 24
4
ROHAN PALEKAR
18 Jan 24
4
Sarah B. Noonberg
18 Jan 24